Russia’s Gamaleya National Research Center for Epidemiology and Microbiology works on the technology accelerating the creation of a novel coronavirus vaccine in case of rapid genomic alterations of the infectious agent, Alexander Gintsburg, the head of the Sputnik V vaccine center, said in a televised interview with Rossiya-1 news channel, an excerpt of which was aired on the channel on Friday.

Mentioning that Russia's Sputnik V vaccine is 96 percent effective, Alexander Gintsburg, the head of the vaccine’s developer, Gamaleya National Research Center for Epidemiology and Microbiology, said it is likely to offer two-year-long protection against the novel coronavirus.